Document:

EX-10.12

 Exhibit 10.12 

CALIBURN INTERNATIONAL CORPORATION 

2018 OMNIBUS EQUITY INCENTIVE PLAN 

FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT 

THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “Agreement”), is entered into as
of            ,              (the “Date of Grant”), by and between Caliburn International Corporation, a
Delaware corporation (the “Company”), and              (the “Grantee”). Capitalized terms used in this Agreement and not otherwise defined herein have the
meanings ascribed to such terms in the Caliburn International Corporation 2018 Omnibus Equity Incentive Plan, as amended, restated or otherwise modified from time to time in accordance with its terms (the “Plan”). 

WHEREAS, the Company has adopted the Plan, pursuant to which restricted stock units (“RSUs”) may be granted; and 

WHEREAS, the Committee has determined that it is in the best interests of the Company and its stockholders to grant the RSUs provided for
herein to the Grantee on the terms and subject to the conditions set forth herein. 
 NOW, THEREFORE, for and in consideration of the
premises and the covenants of the parties contained in this Agreement, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto, for themselves, their successors and assigns, hereby agree as
follows: 
 1. Grant of Restricted Stock Units. 

(a) Grant. The Company hereby grants to the Grantee a total of
             RSUs, on the terms and subject to the conditions set forth in this Agreement and as otherwise provided in the Plan. The RSUs shall vest in accordance with Section 2. The
RSUs shall be credited to a separate book-entry account maintained for the Grantee on the books of the Company. 
 (b)
Incorporation by Reference. The provisions of the Plan are incorporated herein by reference. Except as otherwise expressly set forth herein, this Agreement shall be construed in accordance with the provisions of the Plan and any
interpretations, amendments, rules and regulations promulgated by the Committee from time to time pursuant to the Plan. The Committee shall have final authority to interpret and construe the Plan and this Agreement and to make any and all
determinations under them, and its decision shall be binding and conclusive upon the Grantee and the Grantee’s beneficiary in respect of any questions arising under the Plan or this Agreement. The Grantee acknowledges that the Grantee has
received a copy of the Plan and has had an opportunity to review the Plan and agrees to be bound by all the terms and provisions of the Plan. 

2. Vesting; Settlement. (a) Except as may otherwise be provided herein, the RSUs shall vest in equal installments on each of
the first [three] anniversaries of the Date of Grant (each such date, a “Vesting Date”), subject to the Grantee’s continued employment with or engagement to provide services to, the Company or any of its Affiliates through the
applicable Vesting Date. Any fractional RSU resulting from the application of the vesting schedule shall be aggregated and the RSU resulting from such aggregation shall vest on the final Vesting Date. Upon vesting, the RSUs shall no longer be
subject to cancellation pursuant to Section 4 hereof. 
 (b) Each RSU shall be settled within 60 days following the
Vesting Date in shares of Common Stock. 

 3. Dividend Equivalents. In the event of any issuance of a cash dividend on the
shares of Common Stock (a “Dividend”), the Grantee shall be credited, as of the payment date for such Dividend, with an additional number of RSUs (each, an “Additional RSU”) equal to the quotient obtained by
dividing (x) the product of (i) the number of RSUs granted pursuant to this Agreement and outstanding as of the record date for such Dividend multiplied by (ii) the amount of the Dividend per share, by (y) the Fair Market Value
per share on the payment date for such Dividend, such quotient to be rounded to the nearest hundredth. Once credited, each Additional RSU shall be treated as an RSU granted hereunder and shall be subject to all terms and conditions set forth in this
Agreement and the Plan. 
 4. Termination of Employment or Services. 

(a) Generally. Except as otherwise provided herein, if the Grantee’s employment with or engagement to provide
services to the Company or any of its Affiliates terminates for any reason, all unvested RSUs shall be canceled immediately and the Grantee shall not be entitled to receive any payments with respect thereto.  

(b) Death or Disability. Notwithstanding anything to the contrary in Section 4, if the Grantee’s employment
with or engagement to provide services to the Company or any of its Affiliates terminates due to the Grantee’s death or Disability, then the Grantee will become vested in a pro rata portion of the unvested RSUs, with such pro rata portion
calculated by multiplying the number of RSUs that would have vested on the next vesting date had the Grantee’s employment or service not terminated prior to such vesting date by a fraction, the numerator of which equals the number of days that
the Grantee was employed since the prior vesting date and the denominator of which shall be 365. Each RSU that vests in accordance with this Section 4(b) shall be settled in accordance with the terms of Section 2(b). 

(c) Termination Without Cause. Notwithstanding anything to the contrary in Section 4, if the Grantee’s
employment with or engagement to provide services to the Company or any of its Affiliates is terminated by the Company without Cause, the RSUs will vest on a prorated basis as of the date of termination, which shall be the final Vesting Date, based
on the number of full months of service completed commencing on the Date of Grant and ending on the date of such termination, divided by the number of full months required to achieve complete vesting (with an offset for RSUs previously vested and
settled). Each RSU that vests in accordance with this Section 4(c) shall be settled in accordance with the terms of Section 2(b). 

5. Rights as a Stockholder. The Grantee shall not be deemed for any purpose to be the owner of any shares of Common Stock underlying the
RSUs unless, until and to the extent that (i) the Company shall have issued and delivered to the Grantee the shares of Common Stock underlying the RSUs and (ii) the Grantee’s name shall have been entered as a stockholder of record
with respect to such shares of Common Stock on the books of the Company. The Company shall cause the actions described in clauses (i) and (ii) of the preceding sentence to occur promptly following settlement as contemplated by this Agreement,
subject to compliance with applicable laws. 
 6. Compliance with Legal Requirements. 

(a) Generally. The granting and settlement of the RSUs, and any other obligations of the Company under this Agreement,
shall be subject to all applicable U.S. federal, state and local laws, rules and regulations, all applicable non-U.S. laws, rules and regulations and to such approvals by any regulatory or
governmental agency as may be required. The Grantee agrees to take all steps that the Committee or the Company determines are reasonably necessary to comply with all applicable provisions of U.S. federal and state securities law and non-U.S. securities law in exercising the Grantee’s rights under this Agreement. 

 (b) Tax Withholding. Vesting and settlement of the RSUs shall be
subject to the Grantee’s satisfying any applicable U.S. federal, state and local tax withholding obligations and non-U.S. tax withholding obligations. The Company shall have the right and is hereby
authorized to withhold from any amounts payable to the Grantee in connection with the RSUs or otherwise the amount of any required withholding taxes in respect of the RSUs, their settlement or any payment or transfer of the RSUs or under the Plan
and to take any such other action as the Committee or the Company deem necessary to satisfy all obligations for the payment of such withholding taxes (up to the maximum permissible withholding amounts), including the right to sell the number of
shares of Common Stock that would otherwise be available for delivery upon settlement of the RSUs necessary to generate sufficient proceeds to satisfy withholding obligations. The Grantee may elect to satisfy, and the Company may require the Grantee
to satisfy, in whole or in part, the tax obligations by withholding shares of Common Stock that would otherwise be deliverable to the Grantee upon settlement of the RSUs with a Fair Market Value equal to such withholding liability. 

7. Clawback. Notwithstanding anything to the contrary contained herein, the Committee may cancel the RSU award if the Grantee, without
the consent of the Company, has engaged in or engages in activity that is in conflict with or adverse to the interests of the Company or any Affiliate while employed by or otherwise providing services to the Company or any Affiliate, including fraud
or conduct contributing to any financial restatements or irregularities, or any violation of any of the covenants set forth on Exhibit A attached hereto or any other non-competition, non-solicitation, non-disparagement or non-disclosure covenant or agreement with the Company or any Affiliate (after giving effect to
any applicable cure period set forth therein), as determined by the Committee. In such event, the Grantee will forfeit any compensation, gain or other value realized thereafter on the vesting or settlement of the RSUs, the sale or other transfer of
the RSUs, or the sale of shares of Common Stock acquired in respect of the RSUs (provided that the RSUs vested during the 12-month period immediately prior to the Grantee’s adverse activity), and must
promptly repay such amounts to the Company. If the Grantee receives any amount in excess of what the Grantee should have received under the terms of the RSUs for any reason (including without limitation by reason of a financial restatement, mistake
in calculations or other administrative error), all as determined by the Committee, then the Grantee shall promptly repay any such excess amount to the Company. To the extent required by applicable law or the rules and regulations of the NYSE or any
other securities exchange or interdealer quotation system on which the Common Stock is listed or quoted, or if so required pursuant to a written policy adopted by the Company, the RSUs shall be subject (including on a retroactive basis) to clawback,
forfeiture or similar requirements (and such requirements shall be deemed incorporated by reference into this Agreement). 
 8.
Restrictive Covenants. (a) Without limiting any other non-competition, non-solicitation, non-disparagement or non-disclosure or other similar agreement to which the Grantee may be a party, the Grantee shall be subject to the confidentiality and restrictive covenants set forth on Exhibit A attached hereto, which
Exhibit A is incorporated herein and forms part of this Agreement. 
 (b) In the event that the Grantee violates any
of the restrictive covenants referred to in this Section 8, in addition to any other remedy that may be available at law or in equity, the RSUs shall be automatically forfeited effective as of the date on which such violation first occurs. The
foregoing rights and remedies are in addition to any other rights and remedies that may be available to the Company and shall not prevent (and the Grantee shall not assert that they shall prevent) the Company from bringing one or more actions in any
applicable jurisdiction to recover damages as a result of the Grantee’s breach of such restrictive covenants. 

 9. Miscellaneous. 

(a) Transferability. The RSUs may not be assigned, alienated, pledged, attached, sold or otherwise transferred or
encumbered (a “Transfer”) by the Grantee other than by will or by the laws of descent and distribution, pursuant to a qualified domestic relations order. Any attempted Transfer of the RSUs contrary to the provisions hereof, and the
levy of any execution, attachment or similar process upon the RSUs, shall be null and void and without effect. 
 (b)
Waiver. Any right of the Company contained in this Agreement may be waived in writing by the Committee. No waiver of any right hereunder by any party shall operate as a waiver of any other right, or as a waiver of the same right with respect
to any subsequent occasion for its exercise, or as a waiver of any right to damages. No waiver by any party of any breach of this Agreement shall be held to constitute a waiver of any other breach or a waiver of the continuation of the same breach.

 (c) Section 409A. The RSUs are intended to be exempt from, or compliant with, Section 409A
of the Code. Notwithstanding the foregoing or any provision of the Plan or this Agreement, if any provision of the Plan or this Agreement contravenes Section 409A of the Code or could cause the Grantee to incur any tax, interest or penalties
under Section 409A of the Code, the Committee may, in its sole discretion and without the Grantee’s consent, modify such provision to (i) comply with, or avoid being subject to, Section 409A of the Code, or to avoid the
incurrence of taxes, interest and penalties under Section 409A of the Code, and/or (ii) maintain, to the maximum extent practicable, the original intent and economic benefit to the Grantee of the applicable provision without materially
increasing the cost to the Company or contravening the provisions of Section 409A of the Code. This Section 9(c) does not create an obligation on the part of the Company to modify the Plan or this Agreement and does not guarantee that the
RSUs will not be subject to interest and penalties under Section 409A. 
 (d) General Assets. All amounts
credited in respect of the RSUs to the book-entry account under this Agreement shall continue for all purposes to be part of the general assets of the Company. The Grantee’s interest in such account shall make the Grantee only a general,
unsecured creditor of the Company. 
 (e) Notices. Any notices provided for in this Agreement or the Plan shall be in
writing and shall be deemed sufficiently given if either hand delivered or if sent by fax, pdf/email or overnight courier, or by postage-paid first-class mail. Notices sent by mail shall be deemed received three business days after mailing but in no
event later than the date of actual receipt. Notices shall be directed, if to the Grantee, at the Grantee’s address indicated by the Company’s records, or if to the Company, to the attention of the General Counsel at the Company’s
principal executive office. 
 (f) Severability. The invalidity or unenforceability of any provision of this Agreement
shall not affect the validity or enforceability of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law. 

(g) No Rights to Employment, Directorship or Service. Nothing contained in this Agreement shall be construed as giving
the Grantee any right to be retained, in any position, as an employee or consultant of the Company or any of its Affiliates or shall interfere with or restrict in any way the rights of the Company or any of its Affiliates, which are hereby expressly
reserved, to remove, terminate or discharge the Grantee at any time for any reason whatsoever. 
 (h) Fractional
Shares. In lieu of issuing a fraction of a share of Common Stock resulting from adjustment of the RSUs pursuant to Section 18 of the Plan or otherwise, the Company shall be entitled to pay to the Grantee an amount in cash equal to the Fair
Market Value of such fractional share. 

 (i) Beneficiary. The Grantee may file with the Committee a written
designation of a beneficiary on such form as may be prescribed by the Committee and may, from time to time, amend or revoke such designation. 

(j) Successors. The terms of this Agreement shall be binding upon and inure to the benefit of the Company and its
successors and assigns, and of the Grantee and the beneficiaries, executors, administrators, heirs and successors of the Grantee. 

(k) Entire Agreement. This Agreement (including Exhibit A attached hereto) and the Plan contain the entire
agreement and understanding of the parties hereto with respect to the subject matter contained herein and supersede all prior communications, representations and negotiations in respect thereto, other than any other
non-competition, non-solicitation, non-disparagement or non-disclosure or other similar
agreement to which the Grantee may be a party, the covenants of which shall continue to apply to the Grantee in addition to the covenants in Exhibit A hereto, in accordance with the terms of such agreement. No change, modification or waiver
of any provision of this Agreement shall be valid unless the same be in writing and signed by the parties hereto, except for any changes permitted without consent under Section 23 of the Plan. 

(l) Governing Law and Venue. This Agreement shall be construed and interpreted in accordance with the laws of the State
of Delaware, without regard to principles of conflicts of laws thereof, or principles of conflicts of laws of any other jurisdiction that could cause the application of the laws of any jurisdiction other than the State of Delaware. 

(i) Dispute Resolution; Consent to Jurisdiction. All disputes between or among any Persons arising out of or in any way
connected with the Plan, this Agreement or the RSUs shall be solely and finally settled by the Committee, acting in good faith, the determination of which shall be final. Any matters not covered by the preceding sentence shall be solely and finally
settled in accordance with the Plan, and the Grantee and the Company consent to the personal jurisdiction of the United States federal and state courts sitting in Wilmington, Delaware, as the exclusive jurisdiction with respect to matters arising
out of or related to the enforcement of the Committee’s determinations and resolution of matters, if any, related to the Plan or this Agreement not required to be resolved by the Committee. Each such Person hereby irrevocably consents to the
service of process of any of the aforementioned courts in any such suit, action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, to the last known address of such Person, such service to become
effective ten (10) days after such mailing. 
 (ii) Waiver of Jury Trial. Each party hereto hereby waives, to the
fullest extent permitted by applicable law, any right it may have to a trial by jury in any legal proceeding directly or indirectly arising out of or relating to this Agreement or the transactions contemplated (whether based on contract, tort or any
other theory). Each party hereto (A) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing
waiver and (B) acknowledges that it and the other parties hereto have been induced to enter into this Agreement by, among other things, the mutual waivers and certifications in this section. 

 (m) Headings. The headings of the Sections hereof are provided for
convenience only and are not to serve as a basis for interpretation or construction, and shall not constitute a part, of this Agreement. 

(n) Counterparts. This Agreement may be executed in one or more counterparts (including via facsimile and electronic
image scan (pdf)), each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered
to the other parties. 
 (o) Electronic Signature and Delivery. This Agreement may be accepted by return signature or
by electronic confirmation. By accepting this Agreement, the Grantee consents to the electronic delivery of prospectuses, annual reports and other information required to be delivered by U.S. Securities and Exchange Commission rules (which
consent may be revoked in writing by the Grantee at any time upon three business days’ notice to the Company, in which case subsequent prospectuses, annual reports and other information will be delivered in hard copy to the Grantee). 

(p) Electronic Participation in Plan. The Company may, in its sole discretion, decide to deliver any documents
related to current or future participation in the Plan by electronic means. The Grantee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line
or electronic system established and maintained by the Company or a third party designated by the Company. 
 [Remainder of page
intentionally blank] 

 IN WITNESS WHEREOF, this Restricted Stock Unit Award Agreement has been executed by the
Company and the Grantee as of the day first written above. 
  

			
	CALIBURN INTERNATIONAL CORPORATION
		
	By:	 	  

		 	Name:
		 	Title:
	
	GRANTEE
	
	  

	[Insert Name]

 [Signature Page to Restricted Stock Unit Award Agreement] 

 Exhibit A 

Restrictive Covenants 
 By
accepting the grant of the RSUs hereunder, in addition to any other representations, warranties, and covenants set forth this Agreement, the Grantee agrees to be subject to and comply with the following covenants. 

1. Confidentiality. The Grantee hereby agrees that during the Grantee’s employment or service with the Company or the employer
Affiliate, and thereafter, the Grantee will not disclose confidential or proprietary information, or trade secrets, related to any business of the Company or the employer Affiliate. 

2. Non-Competition. Except as prohibited by law, the Grantee hereby agrees that during the
Grantee’s employment or service with the Company or the employer Affiliate, and for the one year period following the Grantee’s termination of employment or service for any reason, the Grantee will not directly or indirectly, own, manage,
operate, control (including indirectly through a debt or equity investment), provide services to, or be employed by or provide services to, any person or entity engaged in any business that is (i) located in or provides services or products to
a region with respect to which the Grantee had substantial responsibilities while employed or engaged by the Company or the employer Affiliate, and (ii) competitive, with (A) the line of business or businesses of the Company or the
employer Affiliate that the Grantee was employed with or engaged by during the Grantee’s employment or service (including any prospective business to be developed or acquired that was proposed at the date of termination), or (B) any other
business of the Company or the employer Affiliate with respect to which the Grantee had substantial exposure during such employment or service. 

3. Non-Solicitation. Except as prohibited by law, the Grantee further agrees that during the
Grantee’s employment or service with the Company or the employer Affiliate, and for the two-year period thereafter, the Grantee will not, directly or indirectly, on the Grantee’s own behalf or on
behalf of another (i) solicit, recruit, aid or induce any employee of the Company or any of the employer Affiliate to leave their employment with the Company or the employer Affiliate in order to accept employment with or render services to
another person or entity unaffiliated with the Company or the employer Affiliate, or hire or knowingly take any action to assist or aid any other person or entity in identifying or hiring any such employee, or (ii) solicit, aid, or induce any
customer of the Company or any of the employer Affiliate to purchase goods or services then sold by the Company or the employer Affiliate from another person or entity, or assist or aid any other persons or entity in identifying or soliciting any
such customer, or (iii) otherwise interfere with the relationship of the Company or any of the employer Affiliate with any of its employees, customers, agents, or representatives. 

4. The Grantee acknowledges and agrees that irreparable injury will result to the Company, and to its business, in the event of a breach by the
Grantee of any of the Grantee’s covenants and commitments under this Agreement, including the covenants of confidentiality, non-competition and non-solicitation.
The Company reserves all rights to seek any and all remedies and damages permitted under law, including, but not limited to, injunctive relief, equitable relief and compensatory damages. The Grantee acknowledges and agrees the non-competition and non-solicitation provisions contained in this Agreement are expressly intended to benefit the Company (which includes all parents, employer Affiliate
and/or affiliated entities as third party beneficiaries) and its successors and assigns; and the Grantee expressly authorizes the Company (including all third party beneficiaries) and its successors and assigns to enforce these provisions. In the
event of any breach or violation by the Grantee of any of the restrictive covenants in this Exhibit A, the time period of such covenant with respect to the Grantee shall, to the fullest extent permitted by law, be tolled until such breach or
violation is resolved. 

 5. The covenants in this Exhibit A are severable and separate, and the
unenforceability of any specific covenant shall not affect the provisions of any other covenant. If any provision of this Exhibit A relating to the time period, scope, or geographic area of the restrictive covenants shall be declared by a
court of competent jurisdiction or arbitrator to exceed the maximum time period, scope, or geographic area, as applicable, that such court or arbitrator deems reasonable and enforceable, then this Agreement shall automatically be considered to have
been amended and revised to reflect such determination. 
 6. All of the covenants in this Exhibit A shall be construed as an
agreement independent of any other provisions in Exhibit A, and the existence of any claim or cause of action the Grantee may have against the Company (which includes all parents, employer Affiliate and/or affiliated entities as third party
beneficiaries), whether predicated on this Exhibit A or otherwise, shall not constitute a defense to the enforcement by the Company (which includes all parents, employer Affiliate and/or affiliated entities as third party beneficiaries) of
such covenants. 
 7. The Grantee has carefully read and considered the provisions of this Exhibit A and, having done so, agrees that
the restrictive covenants in this Exhibit A impose a fair and reasonable restraint on the Grantee and are reasonably required to protect the interests of the Company (which includes all parents, employer Affiliate and/or affiliated entities
as third party beneficiaries) and their respective officers, directors, employees, and equityholders. 
 * * *tndm-ex105_130.htm

Exhibit 10.5

DEVELOPMENT AGREEMENT

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

This Development Agreement (this “Agreement”) is made and entered into on June 4, 2015 (the “Effective Date”) by and between Tandem Diabetes Care, Inc., a Delaware corporation, having a principal place of business at 11045 Roselle St., San Diego, CA 92121 (“Tandem”) and DexCom, Inc., a Delaware corporation, having a principal place of business at 6340 Sequence Drive, San Diego, CA 92121 (“DexCom”).

Background

	
 
	
A.
	
DexCom is in the business of developing and commercializing continuous glucose monitoring systems, and is currently developing the DexCom G6 System (as defined below).  

	
 
	
B.
	
Tandem has developed, and is developing, current and next generations of insulin infusion pump systems. 

	
 
	
C.
	
The parties believe it is in each of their best interests to enable Tandem to adapt the Tandem Display Device (defined below) to identify, receive, and display information from the DexCom G6 System, which is adapted to communicate information on a one-way basis between a DexCom Sensor (defined below) via the DexCom BT CGM Transmitter (defined below) to an external receiver or other display, such as the Tandem Display Device.

The parties therefore agree as follows:

	
I.
	
Definitions  

	
 
	
1.1.
	
“Affiliates” means any corporation or other entity that is directly or indirectly controlling, controlled by or under common control with a party.  For the purpose of this definition, “control” means the direct or indirect ownership of more than fifty percent (50%) of the capital stock of the subject entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, interests entitled to vote in the election of the corresponding managing authority).

	
 
	
1.2.
	
“Communication Protocol” will have the meaning given to that term in Section 2.2 below.

	
 
	
1.3.
	
“DexCom BT CGM Transmitter” means the transmitter component of the DexCom G6 System that is configured to transmit information from a DexCom Sensor via Bluetooth to any receiver adapted to identify, receive, and display such information, and is also controlled from an authenticated receiver, such as the DexCom Receiver, and the DexCom CGM Smartphone App.

	
 
	
1.4.
	
“DexCom CGM-Enabled Tandem Display Device” means a Tandem Display Device comprising a receiver or other component of the Tandem Insulin Infusion Pump 

 

 

	
 
		
configured to identify, receive, interpret, process and/or display DexCom Sensor Information from a DexCom BT CGM Transmitter and control the DexCom BT CGM Transmitter.  A DexCom CGM-Enabled Tandem Display Device will be independently developed by Tandem pursuant to Section 2.1 and is not, and will not be, a component of a DexCom G6 System. 

	
 
	
1.5.
	
DexCom CGM Smartphone App” means the smartphone application component of the DexCom G6 System that identifies, receives, deciphers and displays information transmitted by a DexCom BT CGM Transmitter from a DexCom Sensor, and also enables control of the DexCom BT CGM Transmitter by receiving and transmitting data to the DexCom G6 System, such as configuration settings and calibration values.

	
 
	
1.6.
	
“DexCom G6 System” means DexCom’s sixth generation continuous glucose monitoring system comprised of the following components, all designed, developed and manufactured by DexCom: a DexCom Sensor, a DexCom BT CGM Transmitter, DexCom Sensor Information, the Communication Protocol, a DexCom Receiver, and the DexCom CGM Smartphone App. 

	
 
	
1.7.
	
“DexCom Receiver” means a component of the DexCom G6 System that identifies, receives, deciphers and displays information transmitted by a DexCom BT CGM Transmitter from a DexCom Sensor, and also enables control of the DexCom Transmitter by receiving and transmitting data to the DexCom G6 System, such as configuration settings and calibration values. 

	
 
	
1.8.
	
“DexCom Sensor” means the component of the DexCom G6 System comprising a continuous glucose monitoring electrode sensor, adapted to (i) penetrate the patient’s skin to come into contact with the patient’s interstitial fluid, (ii) measure interstitial fluid glucose level, and (iii) be operably coupled to a DexCom BT CGM Transmitter to communicate the blood glucose value as measured by the DexCom Sensor to a separate receiver.

	
 
	
1.9.
	
“DexCom Sensor Information” consists of a DexCom BT CGM Transmitter interface spec that specifies contents of the transmitter broadcast message and the available control functions (the “Specification”).  The transmitter broadcast message will contains items such as estimated glucose value, device display time stamp information, the trend arrow and calibration confidence intervals as stored in the DexCom BT CGM Transmitter.  The control functions provide the commands required to start session, stop session and calibrate.  Any additional sensor information to be shared must be agreed in writing by both parties or shall be the result of DexCom’s updating of the Specification, which shall be permitted without requiring compliance with Section 10.7. The term “DexCom Sensor Information” shall in no way be construed to include the Raw Data.  

	
 
	
1.10.
	
“Effective Date” is the date set forth in the preamble above. 

 

2.

 

	
 
	
1.11.
	
"Integrated System" shall mean a Tandem System that implements the Communication Protocol and is capable, among other things, of receiving and displaying continuous glucose monitoring data generated by the DexCom G6 System. 

	
 
	
1.12.
	
"Intellectual Property Rights" means (collectively): copyright rights (including, without limitation, the exclusive right to use, reproduce, modify, distribute, publicly display and publicly perform the copyrighted work), trademark rights (including, without limitation trade names, trademarks, service marks, and trade dress), patent rights (including, without limitation, the exclusive right to make, have made, import, use, sell and offer to sell), trade secrets, rights of publicity, authors’ and moral rights, goodwill and all other intellectual and industrial property rights as may exist now and/or hereafter come into existence and all renewals, reissues and extensions thereof, regardless of whether such rights arise under the laws of the United States or any other U.S. state or other country or jurisdiction.  

 

	
 
	
1.13.
	
“Raw Data” means any raw data used by the DexCom G6 System or any other data generated or stored by the DexCom G6 System that is not included in the definition of DexCom Sensor Information.

	
 
	
1.14.
	
“Tandem Display Device” means a device used in connection with, or component of the, Tandem Insulin Infusion Pump that communicates with and controls the Tandem Insulin Infusion Pump and which also stores and processes data related to the Tandem System.

	
 
	
1.15.
	
“Tandem Insulin Infusion Pump” means a subcutaneous infusion pump for insulin delivery, either alone or together with other medicaments. 

	
 
	
1.16.
	
“Tandem System” means a subcutaneous infusion system comprised of the following components: a Tandem Insulin Infusion Pump and a Tandem Display Device.

	
II.
	
Development & Regulatory

	
 
	
(a)
	
Tandem Responsibilities.  At Tandem’s sole cost, Tandem intends to develop a version of the Tandem System comprising a DexCom CGM-Enabled Tandem Display Device.  Tandem shall be solely responsible for all design, development, regulatory and commercialization activities associated with such DexCom CGM-Enabled Tandem Display Device.  Tandem shall ensure that any DexCom CGM-Enabled Tandem Device shall not interfere with the ability of the DexCom BT CGM Transmitter to remain paired and communicate with the DexCom CGM Smartphone App at all times, notwithstanding any pairing with the Tandem System.

	
 
	
(b)
	
DexCom Responsibilities.  At DexCom’s sole cost, DexCom intends to develop a DexCom G6 System.  DexCom shall be solely responsible for all design, development, regulatory and commercialization activities associated with such DexCom G6 System.  Upon completion of such development, DexCom will provide Tandem with a communication protocol that permits a DexCom CGM-Enabled Tandem Display Device to identify, receive and display DexCom Sensor Information and to control the DexCom 

 

3.

 

	
 
		
BT CGM Transmitter (the “Communication Protocol”). Upon request, DexCom agrees to provide commercially reasonable assistance in response to questions from Tandem to facilitate Tandem’s implementation of the Communication Protocol. In addition, if reasonably necessary for Tandem to secure regulatory approval for the commercialization of a Tandem System, or a component thereof, DexCom agrees to permit Tandem to reference DexCom’s own regulatory filings for the DexCom G6 System.  

	
 
	
(c)
	
Costs.  Each party shall bear its own costs.

	
III.
	
Ownership & License

	
 
	
(a)
	
Ownership.  The parties do not intend for there to be any “joint inventions” under this Agreement and, except as set forth in Section 3.2, this Agreement does not comprise an assignment or license of any intellectual property, trade secrets or confidential information by either party to the other.  DexCom (and/or its Affiliates) will own and retain their Intellectual Property Rights. Tandem (and/or its Affiliates) will own and retain their Intellectual Property Rights.  

	
 
	
(b)
	
License.  DexCom hereby grants Tandem a royalty-free, worldwide, non-exclusive license to (i) use the Communication Protocol for the purpose of developing and commercializing a DexCom CGM-Enabled Tandem Display Device, including the right to make, have made, use, sell, offer to sell, have sold and import the DexCom CGM-Enabled Tandem Display Device; and (ii) use the trademarks, trade names and other marketing names used by DexCom for the DexCom G6 System solely in connection with Tandem’s advertising, promotion, marketing and sale of the Tandem System, and in related brochures and other materials, in full accordance with all guidelines and instructions as DexCom may deliver to Tandem from time to time in DexCom’s sole discretion. 

	
 
	
(c)
	
Limitations on Use.  Tandem agrees not to distribute, license, sublicense or otherwise transfer the Communication Protocol to any third party.  Tandem shall have no right under this Agreement to in any way distribute the Communication Protocol, or to intercept, propagate, reverse engineer, disassemble, de-encrypt, or derive the source code for the software or bios included in any DexCom G6 System, or any component thereof.  Tandem is not granted any right to the Raw Data received or generated by any DexCom G6 System and/or used by it to produce output such as timestamps, measurements or other data, and will not try to derive, de-encrypt or intercept any of such Raw Data.  Tandem shall not access or use any information within the DexCom G6 System other than the information contained in the Specification.  Tandem shall be prohibited from using the Communication Protocol for any purposes other than as set forth in this Agreement. DexCom shall not access or use any information within the Tandem System other than as set forth in this Agreement. 

	
 
	
(d)
	
No Other Restrictions.  For the avoidance of doubt, except as expressly agreed by the parties in writing, (i) DexCom will not be restricted from distributing, licensing, 

 

4.

 

	
 
		
transferring, or otherwise exploiting the DexCom G6 System or any component thereof, or any Intellectual Property Rights therein, and (ii) Tandem will not be restricted from distributing, licensing, transferring, or otherwise exploiting the Tandem System or any component thereof, or any Tandem Intellectual Property Rights therein. 

	
IV.
	
Commercialization

	
 
	
(a)
	
DexCom shall have sole discretion to decide whether to complete development of and commercialize the DexCom G6 System and shall be under no obligation to complete such development or commercialization as a result of this Agreement.

	
 
	
(b)
	
Tandem shall have sole discretion to decide whether to complete development of and commercialize a version of the Tandem System comprising a DexCom CGM-Enabled Tandem Display Device and shall be under no obligation to complete such development or commercialization as a result of this Agreement. Tandem and DexCom will use commercially reasonable efforts to develop a mutually acceptable written plan to provide training and customer and technical support for any mutual customers prior to Tandem’s submission of any application to regulatory authorities to secure regulatory approval for the commercialization of a DexCom CGM-Enabled Tandem Display Device. 

	
 
	
(c)
	
If DexCom and Tandem, respectively, complete the development and commercialization of (i) the DexCom G6 System, and (ii) a DexCom CGM-Enabled Tandem Display Device, then the parties will use commercially reasonable efforts to develop a plan to cooperate on marketing such products to their respective customers. 

	
 
	
(d)
	
Tandem hereby acknowledges that DexCom may discontinue its support of the DexCom G6 System  [***]. DexCom agrees to[***].  Tandem further acknowledges that DexCom has no obligation to[***].

	
V.
	
Representations and Warranties

	
 
	
(a)
	
By Tandem.  Tandem warrants and represents to DexCom that (i) Tandem has the full right and authority to enter into this Agreement and grant the rights granted herein; (ii) Tandem has not previously granted and will not grant any right in conflict with any of the rights granted herein; (iii) to Tandem’s knowledge on the Effective Date, there is no existing or threatened action, suit or claim pending against it with respect to its right to enter into and perform any of its obligations under this Agreement.

	
 
	
(b)
	
By DexCom.  DexCom warrants and represents to Tandem that (i) DexCom has the full right and authority to enter into this Agreement and grant the rights granted herein; (ii) DexCom has not previously granted and will not grant any right in conflict with any of the rights granted herein; (iii) to DexCom’s knowledge on the Effective Date, there is no existing or threatened action, suit or claim pending against it with respect to its right to enter into and perform its obligations under this Agreement.

 

5.

 

	
 
	
(c)
	
Disclaimer of Warranties.  EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION 5, EACH OF TANDEM AND DEXCOM MAKES NO REPRESENTATIONS OR WARRANTIES UNDER THIS AGREEMENT, AND EXPRESSLY DISCLAIMS ANY WARRANTIES EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, AND NON-INFRINGEMENT.

	
VI.
	
Confidentiality

	
 
	
(a)
	
Confidential Information.  Except as expressly provided in this Agreement, during the Term and for[***], any party receiving Confidential Information, as defined below (the “Receiving Party”), will not publish or otherwise disclose and will not use such Confidential Information for any purpose other than carrying out Receiving Party’s obligations under this Agreement. For purposes of this Agreement, “Confidential Information” means any information furnished by a party (the “Disclosing Party”) pursuant to this Agreement which is confidential or proprietary to the Disclosing Party, including, without limitation, the Specifications. Notwithstanding the foregoing, Confidential Information will not include information that, in each case as demonstrated by the Receiving Party with reliable written documentation:

	
 
	
A.
	
was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure;

	
 
	
B.
	
was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving party;

	
 
	
C.
	
became generally available to the public or otherwise part of the public domain after its disclosure hereunder and other than through any act or omission of the Receiving Party in breach of this Agreement; or

	
 
	
D.
	
was subsequently lawfully disclosed to the Receiving Party by a person without breaching a duty of confidentiality or developed by the Receiving Party without use of, reliance on, or reference to any information or materials disclosed by the Disclosing Party.

	
 
	
(b)
	
Permitted Disclosures.  Notwithstanding Section 6.1, a Receiving Party may use or disclose Confidential Information solely to the extent such use or disclosure is reasonably necessary in complying with an order of a court of law, prosecuting or defending litigation, complying with applicable governmental regulations, submitting information to tax or other governmental authorities, or conducting clinical trials, provided that if a Receiving Party is required to make any such disclosure of Confidential Information, it will give the other party reasonable advanced notice of the disclosure, and use its reasonable efforts to secure confidential treatment of the information prior to its disclosure (whether through protective orders or otherwise).

 

6.

 

	
 
	
(c)
	
Return of Confidential Information.  Within 30 days after the effective date of any termination of this Agreement, except to the extent reasonably necessary for a party to exercise any rights that expressly survive the termination of the Agreement, each party will return to the other party (where practicable), or at the Receiving Party’s option, destroy and provide written certification of the destruction of, all tangible materials that contain the Disclosing Party’s Confidential Information.

	
 
	
(d)
	
Confidentiality of Agreement; No Press Release.  Except to the extent required to comply with applicable law, and subject to the requirements of Section 6.2, neither party will make any disclosure to any third party, and no press release will issue, relating to the existence of this Agreement, any term hereof, or any transaction contemplated herein without prior written agreement of the other party. 

	
VII.
	
Indemnification and Defense of Infringement

	
 
	
(a)
	
DexCom will defend and indemnify Tandem, its Affiliates, and each of its directors, officers, employees, agents, successors and assigns (collectively, “Tandem Indemnitees”), against all third-party claims, suits and proceedings, and will hold the Tandem Indemnitees harmless against all judgments, settlements, costs, liabilities and expenses (including without limitation, reasonable attorneys’ fees and litigation costs) (collectively, “Losses”) payable to third parties in connection with such claims, suits and proceedings, to the extent arising from or occurring as a result of: (i) DexCom’s breach of the[***],(ii) the [***], or (iii) physical injury (including death) and/or property damage[***], excluding[***].

	
 
	
(b)
	
Tandem will defend and indemnify DexCom, its Affiliates, and each of its directors, officers, employees, agents, successors and assigns (collectively, “DexCom Indemnitees”), against all third-party claims, suits and proceedings, and will hold the DexCom Indemnitees harmless against all Losses payable to third parties in connection with such claims, suits and proceedings, to the extent arising from or occurring as a result of: (i) Tandem’s breach of the[***], (ii) the[***], or (iii) physical injury (including death) and/or property damage[***], excluding[***]. 

	
 
	
(c)
	
If the manufacture or use of the Integrated System results in a claim, suit or proceeding in which DexCom and Tandem are both entitled to indemnification by the other party pursuant to Sections 7.1 and 7.2, then the parties will discuss in good faith their cooperation in connection with such matter, and shall discuss in good faith an equitable allocation of each party’s indemnification obligations under this Section 7. 

	
 
	
(d)
	
If the manufacture or use of the Integrated System results in a third-party claim, suit, allegation, action or proceeding against Tandem or DexCom alleging infringement of a claim of a patent or alleges infringement or misappropriation of some other intellectual property right of such third party and neither DexCom nor Tandem is entitled to indemnification pursuant to Sections 7.1 and 7.2 (an "Integrated System Infringement Action"), such party will promptly notify the other party in writing. The parties will 

 

7.

 

	
 
		
[***] and [***] of any Integrated System Infringement Action. The parties will [***] concerning any Integrated System Infringement Action and, in the [***] that the[***], the parties[***].

	
 
	
(e)
	
Any party seeking indemnification hereunder (the “Indemnitee”) will promptly notify the indemnifying party (the “Indemnitor”) of any claim, loss, or expense likely to lead to a claim for indemnification, along with all material related information.  The Indemnitor will[***], except that[***].  The Indemnitee may[***].  The Indemnitee will[***].  The Indemnitee may[***].  In addition, the Indemnitee may[***].

	
 
	
(f)
	
Notwithstanding the foregoing, an Indemnitor under this Section 7 has no obligation for any Losses to the extent resulting from (i)[***], or (ii)[***].

	
VIII.
	
Term and Termination

	
 
	
(a)
	
Term.  The initial term of this Agreement will commence on the Effective Date and will continue for five (5) years thereafter (the “Initial Term”). Subsequent to the Initial Term, the term of this Agreement shall automatically renew and be extended for additional one (1) year periods, unless either party notifies the other at least ninety (90) days prior to the expiration of the then current term (the total period during which this Agreement is effective being the “Term”). 

	
 
	
(b)
	
Termination With Cause or Due to Bankruptcy. Either DexCom or Tandem may terminate this Agreement by written notice if the other materially breaches or defaults in the performance of any of its material obligations hereunder, and such default continues for [***] after the non-breaching party provides written notice of the breach to the breaching party. Either party may terminate this Agreement immediately if the other party: (i) liquidates or dissolves, or (ii) becomes subject to any bankruptcy or insolvency proceeding under federal or state law that is not dismissed within[***].  

	
 
	
(c)
	
Effect of Termination.

	
 
	
A.
	
Accrued Rights and Obligations. Termination of this Agreement will not relieve either party for liabilities or obligations incurred pursuant to the terms and conditions of this Agreement prior to termination.  

	
 
	
B.
	
Survival.  In addition, Articles 1, 3.1, 3.3, 3.4, 4.4, 5, 6, 7, 8, 9 and 10 will survive expiration or termination of this Agreement. Further, Section 3.2 will survive expiration or termination of this Agreement to the extent reasonably necessary for Tandem to satisfy ongoing warranty obligations and to provide ongoing service and support to any customer who originally acquired a DexCom CGM-Enabled Tandem Display Device during the Term of this Agreement.

 

8.

 

	
IX.
	
Limitation of Liability

EXCEPT WITH RESPECT TO A BREACH OF AN OBLIGATION UNDER SECTION 6 OR 10.7, OR CLAIMS REQUIRING INDEMNIFICATION PURSUANT TO SECTIONS 7.1, 7.2, 7.3 OR 7.4, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OTHER ENTITY FOR COSTS OF PROCUREMENT OF SUBSTITUTE GOODS, LOST PROFITS, OR ANY OTHER SPECIAL, CONSEQUENTIAL, OR INCIDENTAL DAMAGES, HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY ARISING OUT OF THIS AGREEMENT WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE.  THESE LIMITATIONS SHALL APPLY WHETHER OR NOT THE BREACHING PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.

IF EITHER PARTY TERMINATES THIS AGREEMENT IN ACCORDANCE WITH ANY OF ITS PROVISIONS, NEITHER PARTY SHALL BE LIABLE TO THE OTHER, BECAUSE OF SUCH TERMINATION, FOR COMPENSATION, REIMBURSEMENT OR DAMAGES ON ACCOUNT OF THE LOSS OF PROSPECTIVE PROFITS OR ANTICIPATED SALES OR ON ACCOUNT OF EXPENDITURES, INVENTORY, INVESTMENTS, LEASES OR COMMITMENTS IN CONNECTION WITH THE BUSINESS OR GOODWILL OF TANDEM OR DEXCOM.

	
X.
	
Miscellaneous

	
 
	
(a)
	
Subcontractors.  Either party may subcontract the performance of its obligations under this Agreement to third parties, provided that such third parties are bound by terms and conditions consistent with this Agreement, including restrictions with respect to the protection and use of Confidential Information which are no less stringent than those set forth in this Agreement and each party shall be fully responsible for the performance of its subcontractor(s). 

	
 
	
(b)
	
Force Majeure.  Nonperformance of any party (except for payment obligations) will be excused to the extent that performance is rendered impossible by strike, fire, earthquake, flood, governmental acts or orders or restrictions, or any other reason where failure to perform is beyond the reasonable control and not caused by the gross negligence or willful misconduct of the nonperforming party.

	
 
	
(c)
	
No Implied Waivers; Rights Cumulative.  No failure on the part of DexCom or Tandem to exercise and no delay in exercising any right under this Agreement, or provided by statute or at law or in equity or otherwise, will impair, prejudice or constitute a waiver of any such right, nor will any partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right.

	
 
	
(d)
	
Independent Contractors.  Nothing contained in this Agreement is intended implicitly, or is to be construed, to constitute DexCom or Tandem as partners in the legal sense.  No party hereto will have any express or implied right or authority to assume or create any 

 

9.

 

	
 
		
obligations on behalf of or in the name of any other party or to bind any other party to any contract, agreement or undertaking with any third party.

	
 
	
(e)
	
Notices.  All notices, requests and other communications hereunder will be in writing and will be personally delivered or sent by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to the other parties hereto:

 

	
 
	
Tandem:
	
Tandem Diabetes Care

	
 
	

	
11045 Roselle St.

	
 
	

	
San Diego, CA 92121

	
 
	

	
Attn:  Chief Executive Officer 
with copy to: General Counsel

	
 
	
DexCom:
	
DexCom, Inc.

	
 
	

	
6340 Sequence Drive
San Diego, CA 92121
Attn: Legal Department

	
 
	
(f)
	
Assignment.  This Agreement will not be assignable by either party to any third party without the written consent of the other party hereto; provided that either party may assign this Agreement to a third party acquiring all or substantially all of the business or assets of such party, including by way of merger, sale of assets, consolidation, change of control or operation of law upon written notice to the other party to this Agreement; provided further however, that Tandem shall make no such assignment to a competitor of DexCom without DexCom’s written consent, which determination and consent shall be made by DexCom in its sole discretion. 

	
 
	
(g)
	
Standstill.  Except as permitted by the last sentence of this Section 10.7, during the Term of this Agreement and for a period of twelve (12) months thereafter,  without the prior written consent of the Board of Directors of Tandem, DexCom and its officers, directors and Affiliates, will not directly or indirectly in any manner: (i) acquire, announce an intention to acquire, or agree to acquire, directly or indirectly, alone or in concert with others, by purchase, gift or otherwise, any direct or indirect beneficial ownership (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934 (the “Exchange Act”)) or interest in any securities or direct or indirect rights, warrants or options to acquire, or securities convertible into or exchangeable for, any securities of Tandem (ii) make, or in any way participate in, directly or indirectly, alone or in concert with others, any “solicitation” of “proxies” to vote (as such terms are used in the proxy rules of the SEC promulgated pursuant to Section 14 of the Exchange Act) any securities of Tandem with respect to any business combination, restructuring, recapitalization or similar transaction; (iii) form, join or in any way participate in a “group” within the meaning of Section 13(d)(3) of the Exchange Act with respect to any voting securities of Tandem; (iv) acquire, announce an intention to acquire, or agree to acquire, directly or indirectly, alone or in concert with others, by purchase, exchange or otherwise, (a) any of the assets, tangible or intangible, of Tandem or (b) direct or indirect rights, warrants or options to acquire any assets of Tandem, other than in the ordinary course of business; (v) enter into 

 

10.

 

	
 
		
any arrangement or understanding with, or otherwise assist or encourage, others to do any of the actions restricted or prohibited under clauses (i), (ii), (iii) or (iv) of this Section 10.7; (vi) otherwise act in concert with others, to seek to offer to Tandem or any of its stockholders any business combination, restructuring, recapitalization or similar transaction to or with Tandem, or (vii) take any action to control the management, Board of Directors or policies of Tandem. Notwithstanding the above, cumulative acquisitions by DexCom, including any Affiliate of DexCom, of less than one percent (1%) of Tandem's outstanding common shares shall not be deemed a breach of this provision. 

	
 
	
(h)
	
Modifications.  No amendment or modification of any provision of this Agreement will be effective unless in writing signed by all parties hereto.  No provision of this Agreement will be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by all parties.

	
 
	
(i)
	
Severability.  If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, all other provisions hereof will remain in full force and effect in such jurisdiction and will be liberally construed in order to carry out the intentions of the parties hereto as nearly as may be possible.  Such invalidity, illegality or unenforceability will not affect the validity, legality or enforceability of such provision in any other jurisdiction.

	
 
	
(j)
	
Governing Law.  This Agreement and any dispute arising from the performance or breach hereof will be governed by and construed and enforced in accordance with, the laws of the State of Delaware without regard for conflicts of laws principles. 

	
 
	
(k)
	
Counterparts.  This Agreement may be executed in two or more counterparts, each of which will be deemed an original, and all of which together, will constitute one and the same instrument.

	
 
	
(l)
	
Headings.  Headings used herein are for convenience only and will not in any way affect the construction of or be taken into consideration in interpreting this Agreement.

	
 
	
(m)
	
Entire Agreement.  This Agreement, including the Attachments attached hereto, constitutes the entire agreement with respect to the subject matter hereof, and supersedes all prior or contemporaneous understandings or agreements, whether written or oral, between DexCom and Tandem with respect to such subject matter. For the avoidance of doubt, DexCom and Tandem acknowledge and agree that this Agreement does not terminate, amend or otherwise modify either (i) the Amended and Restated Development and Commercialization Agreement between the parties dated as of January 4, 2013 or (ii) the G5 Development Agreement between the parties entered into concurrently with this Agreement.

[Signature Page Follows]

 

 

11.

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed by duly authorized officers or representatives as of the date first above written.

 

 

		
	
DexCom, Inc.
	
Tandem Diabetes Care, Inc.

	
By: /s/ Kevin Sun for Jess Roper
	
By: /s/ Kim D. Blickenstaff

	
Jess Roper
	
Print Name: Kim D. Blickenstaff

	
Title:  Senior Vice President
	
Title: President & Chief Executive Officer

	
and Chief Financial Officer
	
 

	
 
	
 

	
Date: June 4, 2015
	
Date: June 4, 2015

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]